Biotechnology Company
Appears in 1 story
On June 8, 2026, reported Phase 1/2 data showing vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted, RAS-mutant metastatic pancreatic cancer, with no discontinuations due to side effects; planning Phase 3 first-line trial later in 2026
On May 31, Revolution Medicines presented the full Phase 3 RASolute 302 dataset at the ASCO plenary in Chicago, simultaneously published in the New England Journal of Medicine. Daraxonrasib cut the risk of death by 60%. The drug produced a 33.2% objective response rate versus 11.8% on chemotherapy and nearly halved the rate at which patients' pain worsened.
Updated Jun 8
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
